Literature DB >> 26602992

Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.

Wanqiong Qiao1, Yao Yang1, Robert Sebra1,2, Geetu Mendiratta1, Andrea Gaedigk3,4, Robert J Desnick1, Stuart A Scott1.   

Abstract

The cytochrome P450-2D6 (CYP2D6) enzyme metabolizes ∼25% of common medications, yet homologous pseudogenes and copy number variants (CNVs) make interrogating the polymorphic CYP2D6 gene with short-read sequencing challenging. Therefore, we developed a novel long-read, full gene CYP2D6 single molecule real-time (SMRT) sequencing method using the Pacific Biosciences platform. Long-range PCR and CYP2D6 SMRT sequencing of 10 previously genotyped controls identified expected star (*) alleles, but also enabled suballele resolution, diplotype refinement, and discovery of novel alleles. Coupled with an optimized variant-calling pipeline, CYP2D6 SMRT sequencing was highly reproducible as triplicate intra- and inter-run nonreference genotype results were completely concordant. Importantly, targeted SMRT sequencing of upstream and downstream CYP2D6 gene copies characterized the duplicated allele in 15 control samples with CYP2D6 CNVs. The utility of CYP2D6 SMRT sequencing was further underscored by identifying the diplotypes of 14 samples with discordant or unclear CYP2D6 configurations from previous targeted genotyping, which again included suballele resolution, duplicated allele characterization, and discovery of a novel allele and tandem arrangement. Taken together, long-read CYP2D6 SMRT sequencing is an innovative, reproducible, and validated method for full-gene characterization, duplication allele-specific analysis, and novel allele discovery, which will likely improve CYP2D6 metabolizer phenotype prediction for both research and clinical testing applications.
© 2015 WILEY PERIODICALS, INC.

Entities:  

Keywords:  CYP2D6; Pacific Biosciences; gene duplication; long-read sequencing; pharmacogenetics; pharmacogenomics; single molecule real-time (SMRT) sequencing

Mesh:

Substances:

Year:  2015        PMID: 26602992      PMCID: PMC4752389          DOI: 10.1002/humu.22936

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

1.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

2.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

3.  MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island.

Authors:  Philip M Ashton; Satheesh Nair; Tim Dallman; Salvatore Rubino; Wolfgang Rabsch; Solomon Mwaigwisya; John Wain; Justin O'Grady
Journal:  Nat Biotechnol       Date:  2014-12-08       Impact factor: 54.908

Review 4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Authors:  J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2015-06-29       Impact factor: 6.875

5.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

Authors:  S Kimura; M Umeno; R C Skoda; U A Meyer; F J Gonzalez
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

Review 6.  Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.

Authors:  J Kevin Hicks; Jesse J Swen; Andrea Gaedigk
Journal:  Curr Drug Metab       Date:  2014-02       Impact factor: 3.731

7.  CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.

Authors:  Andrea Gaedigk; Amanda K Riffel; J Steven Leeder
Journal:  J Mol Diagn       Date:  2015-09-01       Impact factor: 5.568

8.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

9.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genomics       Date:  2010-04       Impact factor: 4.639

10.  An improved allele-specific PCR primer design method for SNP marker analysis and its application.

Authors:  Jing Liu; Shunmou Huang; Meiyu Sun; Shengyi Liu; Yumei Liu; Wanxing Wang; Xiurong Zhang; Hanzhong Wang; Wei Hua
Journal:  Plant Methods       Date:  2012-08-24       Impact factor: 4.993

View more
  37 in total

1.  Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Authors:  Wanqiong Qiao; Suparna Martis; Geetu Mendiratta; Lisong Shi; Mariana R Botton; Yao Yang; Andrea Gaedigk; Raymon Vijzelaar; Lisa Edelmann; Ruth Kornreich; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

Review 2.  Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  NPJ Genom Med       Date:  2020-03-05       Impact factor: 8.617

Review 3.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

Review 4.  Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Mariana R Botton; Yao Yang; Erick R Scott; Stephen B Ellis; Richard Wallsten; Tom Kaszemacher; Xiang Zhou; Rong Chen; Paola Nicoletti; Hetanshi Naik; Eimear E Kenny; Aida Vega; Eva Waite; George A Diaz; Joel Dudley; Jonathan L Halperin; Lisa Edelmann; Andrew Kasarskis; Jean-Sébastien Hulot; Inga Peter; Erwin P Bottinger; Kurt Hirschhorn; Pamela Sklar; Judy H Cho; Robert J Desnick; Eric E Schadt
Journal:  Pharmacogenomics       Date:  2017-10-06       Impact factor: 2.533

Review 5.  Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Authors:  Volker M Lauschke; Lili Milani; Magnus Ingelman-Sundberg
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

Review 6.  How do emerging long-read sequencing technologies function in transforming the plant pathology research landscape?

Authors:  Islam Hamim; Ken-Taro Sekine; Ken Komatsu
Journal:  Plant Mol Biol       Date:  2022-08-13       Impact factor: 4.335

Review 7.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

8.  Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population.

Authors:  Koya Fukunaga; Eiji Hishinuma; Masahiro Hiratsuka; Ken Kato; Takuji Okusaka; Takeo Saito; Masashi Ikeda; Teruhiko Yoshida; Hitoshi Zembutsu; Nakao Iwata; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2020-08-05       Impact factor: 3.172

Review 9.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

10.  TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.

Authors:  Crescenzio Francesco Minervini; Cosimo Cumbo; Paola Orsini; Claudia Brunetti; Luisa Anelli; Antonella Zagaria; Angela Minervini; Paola Casieri; Nicoletta Coccaro; Giuseppina Tota; Luciana Impera; Annamaria Giordano; Giorgina Specchia; Francesco Albano
Journal:  Diagn Pathol       Date:  2016-10-10       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.